Cargando…

An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression

BACKGROUND: Patients who receive immunotherapeutics may develop an atypical response pattern, which warrants further investigation into the potential benefits and risks for patients who continue immunotherapy beyond RECIST-defined disease progression. METHODS: A pooled analysis including all submiss...

Descripción completa

Detalles Bibliográficos
Autores principales: Beaver, Julia A., Hazarika, Maitreyee, Mulkey, Flora, Mushti, Sirisha, Chen, Huanyu, He, Kun, Sridhara, Rajeshwari, Goldberg, Kirsten B., Chuk, Meredith K., Chi, Dow-Chung, Chang, Jennie, Barone, Amy, Balasubramaniam, Sanjeeve, Blumenthal, Gideon M., Keegan, Patricia, Pazdur, Richard, Theoret, Marc R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806609/
https://www.ncbi.nlm.nih.gov/pubmed/29361469
http://dx.doi.org/10.1016/S1470-2045(17)30846-X
_version_ 1783299157623046144
author Beaver, Julia A.
Hazarika, Maitreyee
Mulkey, Flora
Mushti, Sirisha
Chen, Huanyu
He, Kun
Sridhara, Rajeshwari
Goldberg, Kirsten B.
Chuk, Meredith K.
Chi, Dow-Chung
Chang, Jennie
Barone, Amy
Balasubramaniam, Sanjeeve
Blumenthal, Gideon M.
Keegan, Patricia
Pazdur, Richard
Theoret, Marc R.
author_facet Beaver, Julia A.
Hazarika, Maitreyee
Mulkey, Flora
Mushti, Sirisha
Chen, Huanyu
He, Kun
Sridhara, Rajeshwari
Goldberg, Kirsten B.
Chuk, Meredith K.
Chi, Dow-Chung
Chang, Jennie
Barone, Amy
Balasubramaniam, Sanjeeve
Blumenthal, Gideon M.
Keegan, Patricia
Pazdur, Richard
Theoret, Marc R.
author_sort Beaver, Julia A.
collection PubMed
description BACKGROUND: Patients who receive immunotherapeutics may develop an atypical response pattern, which warrants further investigation into the potential benefits and risks for patients who continue immunotherapy beyond RECIST-defined disease progression. METHODS: A pooled analysis including all submissions to U.S. Food and Drug Administration (FDA) in support of marketing applications for anti-PD-1 antibodies and approved by FDA for treatment of patients with unresectable or metastatic melanoma (MM) was conducted to evaluate the potential benefits and safety of treatment beyond progression (TBP). Trials had to allow for continuation of the antibody beyond RECIST-defined progression (RECISTPD) in the anti-PD-1 arm. Any patient receiving the anti-PD-1 antibody after their RECISTPD date were included in the TBP cohort and analyzed descriptively at baseline and at time of progression with the cohort not receiving treatment beyond progression (noTBP). Patients in the TBP cohort had target lesion (TL) response after progression analyzed relative to PD and baseline TL burden. FINDINGS: Of 2624 pooled patients receiving immunotherapy, 52% (1361/2624) had progressive disease (PD); of these, 51% (692/1361) received continued anti-PD-1 antibody beyond RECIST-defined progression. Nineteen percent (95/500) of patients in TBP cohort with evaluable assessments experienced a ≥ 30% decrease in tumor burden, when considering burden at RECISTPD as the reference, representing 14% (95/692) of those TBP and 3·6% (95/2624) of all immunotherapy treated patients. Overall survival (OS) was greater in the TBP cohort compared with the noTBP cohort. One of the pooled trials was a double-blind, randomized, active-controlled trial evaluating an anti-PD-1 antibody vs. chemotherapy in which OS appeared similar in both arms for patients treated beyond progression and longer than the noTBP cohorts. Immune-related adverse events (irAE) up to 90-days from discontinuation were similar between the TBP cohort and the noTBP cohort. INTERPRETATION: Continuation of TBP in the product labeling of these immunotherapies has not been recommended as the clinical benefit remains to be proven. TBP with anti-PD-1 antibody therapy may be appropriate for select patients with MM, identified by specific criteria at the time of progression, based on the potential for late responses in the setting of the known toxicity profile. FUNDING: none
format Online
Article
Text
id pubmed-5806609
institution National Center for Biotechnology Information
language English
publishDate 2018
record_format MEDLINE/PubMed
spelling pubmed-58066092019-02-01 An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression Beaver, Julia A. Hazarika, Maitreyee Mulkey, Flora Mushti, Sirisha Chen, Huanyu He, Kun Sridhara, Rajeshwari Goldberg, Kirsten B. Chuk, Meredith K. Chi, Dow-Chung Chang, Jennie Barone, Amy Balasubramaniam, Sanjeeve Blumenthal, Gideon M. Keegan, Patricia Pazdur, Richard Theoret, Marc R. Lancet Oncol Article BACKGROUND: Patients who receive immunotherapeutics may develop an atypical response pattern, which warrants further investigation into the potential benefits and risks for patients who continue immunotherapy beyond RECIST-defined disease progression. METHODS: A pooled analysis including all submissions to U.S. Food and Drug Administration (FDA) in support of marketing applications for anti-PD-1 antibodies and approved by FDA for treatment of patients with unresectable or metastatic melanoma (MM) was conducted to evaluate the potential benefits and safety of treatment beyond progression (TBP). Trials had to allow for continuation of the antibody beyond RECIST-defined progression (RECISTPD) in the anti-PD-1 arm. Any patient receiving the anti-PD-1 antibody after their RECISTPD date were included in the TBP cohort and analyzed descriptively at baseline and at time of progression with the cohort not receiving treatment beyond progression (noTBP). Patients in the TBP cohort had target lesion (TL) response after progression analyzed relative to PD and baseline TL burden. FINDINGS: Of 2624 pooled patients receiving immunotherapy, 52% (1361/2624) had progressive disease (PD); of these, 51% (692/1361) received continued anti-PD-1 antibody beyond RECIST-defined progression. Nineteen percent (95/500) of patients in TBP cohort with evaluable assessments experienced a ≥ 30% decrease in tumor burden, when considering burden at RECISTPD as the reference, representing 14% (95/692) of those TBP and 3·6% (95/2624) of all immunotherapy treated patients. Overall survival (OS) was greater in the TBP cohort compared with the noTBP cohort. One of the pooled trials was a double-blind, randomized, active-controlled trial evaluating an anti-PD-1 antibody vs. chemotherapy in which OS appeared similar in both arms for patients treated beyond progression and longer than the noTBP cohorts. Immune-related adverse events (irAE) up to 90-days from discontinuation were similar between the TBP cohort and the noTBP cohort. INTERPRETATION: Continuation of TBP in the product labeling of these immunotherapies has not been recommended as the clinical benefit remains to be proven. TBP with anti-PD-1 antibody therapy may be appropriate for select patients with MM, identified by specific criteria at the time of progression, based on the potential for late responses in the setting of the known toxicity profile. FUNDING: none 2018-01-18 2018-02 /pmc/articles/PMC5806609/ /pubmed/29361469 http://dx.doi.org/10.1016/S1470-2045(17)30846-X Text en http://creativecommons.org/licenses/by-nc-nd/4.0/ This manuscript version is made available under the CC BY-NC-ND 4.0 license.
spellingShingle Article
Beaver, Julia A.
Hazarika, Maitreyee
Mulkey, Flora
Mushti, Sirisha
Chen, Huanyu
He, Kun
Sridhara, Rajeshwari
Goldberg, Kirsten B.
Chuk, Meredith K.
Chi, Dow-Chung
Chang, Jennie
Barone, Amy
Balasubramaniam, Sanjeeve
Blumenthal, Gideon M.
Keegan, Patricia
Pazdur, Richard
Theoret, Marc R.
An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
title An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
title_full An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
title_fullStr An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
title_full_unstemmed An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
title_short An FDA Pooled Analysis of Patients with Melanoma Treated with an Anti-PD1 Antibody Beyond RECIST Progression
title_sort fda pooled analysis of patients with melanoma treated with an anti-pd1 antibody beyond recist progression
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5806609/
https://www.ncbi.nlm.nih.gov/pubmed/29361469
http://dx.doi.org/10.1016/S1470-2045(17)30846-X
work_keys_str_mv AT beaverjuliaa anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT hazarikamaitreyee anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT mulkeyflora anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT mushtisirisha anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT chenhuanyu anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT hekun anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT sridhararajeshwari anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT goldbergkirstenb anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT chukmeredithk anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT chidowchung anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT changjennie anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT baroneamy anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT balasubramaniamsanjeeve anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT blumenthalgideonm anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT keeganpatricia anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT pazdurrichard anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT theoretmarcr anfdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT beaverjuliaa fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT hazarikamaitreyee fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT mulkeyflora fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT mushtisirisha fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT chenhuanyu fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT hekun fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT sridhararajeshwari fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT goldbergkirstenb fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT chukmeredithk fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT chidowchung fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT changjennie fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT baroneamy fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT balasubramaniamsanjeeve fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT blumenthalgideonm fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT keeganpatricia fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT pazdurrichard fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression
AT theoretmarcr fdapooledanalysisofpatientswithmelanomatreatedwithanantipd1antibodybeyondrecistprogression